EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 截至本公告日期，本公司董事會包括董事長兼執行董事Hao Hong博士，執行董事楊蕊女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非執行董事孫雪嬌博士、侯欣一博士及謝維愷先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 凱萊英醫藥集團（天津）股份有限公司 | | 股份代號 | 06821 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | ...

Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue was approximately RMB 6,670,181 thousand, representing a growth of 14.91% compared to RMB 5,804,657 thousand in the previous year[5]. - The gross profit margin increased to approximately 41.59%, up by 0.56 percentage points from 41.03% in the previous year[6]. - The net profit attributable to shareholders was approximately RMB 1,132,570 thousand, a 19.35% increase from RMB 948,950 thousand in the previous year[6]. - The adjusted net profit attributable to shareholders under non-IFRS was approximately RMB 1,253,488 thousand, reflecting a significant growth of 56.09% compared to RMB 803,069 thousand in the previous year[6]. - In 2025, the company achieved revenue of RMB 6,670.18 million, representing a year-on-year growth of 14.91%[38]. - The gross profit margin for 2025 was 41.59%, an increase of 0.56 percentage points compared to the previous year[38]. - Adjusted net profit attributable to shareholders reached RMB 1,253.49 million, a growth of 56.09% compared to 2024[38]. - Net profit increased by 20.04% to RMB 1,126.64 million in 2025, with a net profit margin of 16.98%, up 0.63 percentage points from 2024[53]. Revenue Breakdown - Revenue from large pharmaceutical companies was RMB 2,916 million, an increase of 8.36%, while revenue from small and medium-sized pharmaceutical companies was RMB 3,755 million, up by 20.57%[11]. - Revenue from overseas clients was RMB 4,921 million, reflecting a year-over-year growth of 14.85%, while domestic market revenue was RMB 1,749 million, up by 15.09%[12]. - Revenue from the domestic market in China was RMB 1,749,302,000 for 2025, up from RMB 1,519,908,000 in 2024, representing a growth of 15.1%[164]. - Revenue from overseas markets increased to RMB 4,920,879,000 in 2025, compared to RMB 4,284,749,000 in 2024, marking a growth of 14.9%[164]. - The sales revenue from small molecule CDMO business was RMB 4,734,651,000 in 2025, up from RMB 4,570,728,000 in 2024, reflecting a growth of 3.6%[169]. Order Backlog and Client Growth - The total order backlog, excluding recognized revenue, reached USD 1.385 billion, an increase of 31.65% year-over-year, indicating strong demand in the chemical and biological macromolecule sectors[9]. - The company added over 300 new CDMO clients in the fiscal year, expanding its customer base significantly[11]. Research and Development - The company is expanding its data intelligence capabilities, applying an intelligent drug vigilance platform to over 40 innovative drug clinical projects[22]. - The company has published 51 research papers in leading international journals, with 17 papers having an impact factor exceeding 10, showcasing its commitment to innovation in continuous reaction and biosynthesis technologies[27]. - The company plans to continue to increase R&D investment, establishing a collaborative R&D platform to enhance process synthesis design and optimization, thereby promoting order completion[87]. - The company invested RMB 593.26 million in R&D in 2025, accounting for 8.89% of total revenue, a decrease of 3.45% from the previous year[38]. Financial Position - The company's total assets increased to RMB 20,277,466 thousand, a growth of 5.13% from RMB 19,288,556 thousand in the previous year[8]. - The cash and bank balance rose to RMB 6,320,950 thousand, representing a 9.18% increase from RMB 5,789,408 thousand in the previous year[8]. - The total equity attributable to shareholders as of December 31, 2025, was approximately RMB 17,646.14 million, compared to RMB 16,862.57 million as of December 31, 2024[72]. - The company maintains a healthy financial position with cash and cash equivalents exceeding RMB 6.3 billion, providing flexibility for further development and overseas expansion[93]. Corporate Governance - The roles of the Chairman and CEO are distinct, in accordance with corporate governance guidelines, to ensure accountability and transparency[95]. - The board of directors is composed of nine members, including three independent non-executive directors, ensuring a balance of power and responsibilities[96]. - The company is committed to maintaining high corporate governance standards, ensuring shareholder rights and enhancing corporate value[94]. Strategic Plans and Future Outlook - The company anticipates a revenue growth of 19-22% for 2026, following a return to a growth trajectory in 2025[81]. - The company is focusing on the development of emerging businesses such as chemical macromolecules and biological macromolecules to capture market opportunities[81]. - The company plans to expand its overseas production capacity strategically to enhance its market share and meet the growing global demand for its services[31]. - The company aims to optimize profitability by improving the gross margin of its small molecule CDMO business and controlling production costs[84]. Employee and Talent Management - A total of 201 senior talents were recruited in 2025, with nearly 50% holding doctoral degrees, contributing to a workforce of 10,617 employees, of which approximately 78.2% have a bachelor's degree or higher[33]. - The management team is stable and experienced, with an average of over 20 years in their respective fields, contributing to the company's governance and strategic direction[93]. Risks and Challenges - Potential risks include major drug recalls, operational challenges in clinical projects, and regulatory compliance issues, which the company is actively addressing[92]. - The group is subject to a statutory income tax rate of 25% for 2025, as it no longer qualifies for the reduced rate of 15% due to a decrease in revenue from high-tech industries[174].

Group 1 - The core point of the article is that Schroders PLC has increased its stake in Kailaiying (06821.HK) by purchasing 88,500 shares at an average price of HKD 79.0296 per share, totaling approximately HKD 6.9941 million [1] - Following this acquisition, Schroders PLC's total shareholding in Kailaiying has risen to 5.6214 million shares, increasing its ownership percentage from 19.88% to 20.20% [1]

凯莱英医药集团（天津）股份有限公司 内部控制审计报告 2025年度 凯莱英医药集团（天津）股份有限公司 目 录 页 次 内部控制审计报告 1 - 2 内部控制审计报告 安永华明（2026）专字第70055189_B03号 凯莱英医药集团（天津）股份有限公司 凯莱英医药集团（天津）股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审 计了凯莱英医药集团（天津）股份有限公司2025年12月31日的财务报告内部控制的有 效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制 评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是凯莱英医药集 团（天津）股份有限公司董事会的责任。 二、注册会计师的责任 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况 的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内 部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，凯莱英医药集团（天津）股份有限公司于2025年12月3 ...

第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 2025 年度募集资金存放与使用情况的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"） 持续督导的保荐机构，根据《上市公司募集资金监管规则》、《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等法律和规范性文件的 要求，对凯莱英 2025 年度募集资金存放与使用情况进行了审慎核查。具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 截至 2025 年 12 月 31 日，公司使用闲置募集资金购买的理财产品情况如下： | | | 产品名称 | 产品类 | | 产品发行 | 金额（人民币 | | 预期年化收益 | 是 否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 购买主体 | | | | | | | 期间 | | | | | | | 型 | | 主体 | 万元） | | 率（%） | 到 | | | ...

凯莱英医药集团（天津）股份有限公司 已审财务报表 目 录 2025年度 凯莱英医药集团（天津）股份有限公司 | | 页 | | 次 | | --- | --- | --- | --- | | 审计报告 | 1 | - | 5 | | 已审财务报表 | | | | | 合并资产负债表 | 6 | - | 8 | | 合并利润表 | 9 | - | 10 | | 合并股东权益变动表 | 11 | - | 12 | | 合并现金流量表 | 13 | - | 14 | | 公司资产负债表 | 15 | - | 16 | | 公司利润表 | | 17 | | | 公司股东权益变动表 | 18 | - | 19 | | 公司现金流量表 | 20 | - | 21 | | 财务报表附注 | 22 | - | 121 | | 补充资料 | | | | | 1.非经常性损益明细表 | | 1 | | | 2.净资产收益率和每股收益 | | 1 | | | 3.中国企业会计准则与国际财务报告准则编报差异调节表 | | 2 | | 审计报告 安永华明（2026）审字第70055189_B01号 凯莱英医药集团（天津）股份有限公司 ...

Group 1 - The core point of the article is that Schroders PLC has increased its stake in Kailaiying (06821.HK) by purchasing 88,500 shares at an average price of HKD 79.0296 per share, totaling approximately HKD 6.9941 million [1] - Following this acquisition, Schroders PLC's total shareholding in Kailaiying has risen to 5.6214 million shares, increasing its ownership percentage from 19.88% to 20.20% [1]

Group 1 - Schroders PLC increased its stake in Kairong (06821) by 88,500 shares at a price of HKD 79.0296 per share, totaling approximately HKD 6.9941 million [1] - Following the increase, Schroders PLC's total shareholding in Kairong reached 5.6214 million shares, representing a 20.2% ownership stake [1]

Core Viewpoint - Kailaiying (002821.SZ) reported a total operating revenue of 6.67 billion yuan for the year 2025, reflecting a year-on-year growth of 14.91% and a constant currency growth of 16.78% [1] Financial Performance - The company achieved revenue of 2.04 billion yuan in the fourth quarter, representing a quarter-on-quarter increase of 41.53% and a year-on-year increase of 22.59%, with a constant currency growth of 30.84% [1] - The net profit attributable to shareholders reached 1.13 billion yuan, marking a year-on-year increase of 19.35% [1] - Adjusted net profit was reported at 1.25 billion yuan, showing a significant year-on-year growth of 56.09% [1] Shareholder Returns - The company declared a cash dividend of 13 yuan for every 10 shares to all shareholders [1]

凯莱英医药集团（天津）股份有限公司 2025 年年度报告商誉减值 凯莱英医药集团（天津）股份有限公司 一、是否进行减值测试 是 □否 二、是否在减值测试中取得以财务报告为目的的评估报告 是 □否 | 资产组名称 | 评估机构 | 评估师 | 评估报告编号 | | 评估价值类型 | 评估结果 | | --- | --- | --- | --- | --- | --- | --- | | 临床研究服务业 务线含商誉的资 | 中发国际资产评 估有限公司 | 寇迎伟、彭艳芳 | 中发财评字 [2026]第 号 | 027 | 可收回价值 | 50,700,000.00 | | 产组 | | | | | | | | 临床数据管理和 统计服务业务线 | 中发国际资产评 估有限公司 | 寇迎伟、王慧芳 | 中发财评字 [2026]第 号 | 035 | 可收回价值 | 111,400,000.00 | | 含商誉的资产组 | | | | | | | 三、是否存在减值迹象 | 资产组名称 | 是否存在减值 迹象 | | 备注 | 是否计提减值 | 备注 | 减值依据 | 备注 | | --- | --- | --- | -- ...